ALS Research Collaborative

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorALS Therapy Development Institute

About this trial

The goal of this natural history study is to learn more about the biological and clinical aspects of amyotrophic lateral sclerosis (ALS). This study's findings will help with drug discovery, biomarker discovery, and outcome measure validation. Adults living with ALS, other motor neuron diseases (MND), a known mutation related to ALS and healthy volunteers contribute prospective and retrospective data to this study remotely. The study is sponsored and conducted by the ALS Therapy Development Institute.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

18 years of age or older

Can communicate in written English

Has a diagnosis of ALS/MND or is a known carrier of an ALS associated mutation

Disqualifiers

Significant cognitive impairment that would prevent individual completion and understanding of the informed consent process.

Trial population

Participants can be located anywhere but require internet access.

Trial design

Design model

Case-control

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

2,000 Participants
are grouped into 3 trial groups
Group A: Person living with ALS/MND
Group B: Asymptomatic gene carrier
Group C: Healthy Volunteer

Trial outcomes

Primary outcomes

1

ALS Functional Rating Scale - Revised (ALSFRS-R)

A questionnaire completed by the participant that assesses 12 daily functions of living on a 0 (severe symptoms) to 4 (minimal to no symptoms) integer scale.

Time frame
Monthly, through study completion, an average of 1 year

Secondary outcomes

1

Machine-Learning Based Speech Scoring

Participants submit a scripted voice recording of 5 different, short phrases that are then scored by a machine-learning based algorithm that assess dysarthria on a non-integer scale of 0 (fully impaired) to 4 (normal speech)

Time frame
Monthly, through study completion, an average of 1 year
2

Limb-based Accelerometry

Participants wear four, ActiGraph devices on each limb. Passive and active (video-directed) wear time data is collected over one week. The devices measure acceleration and represent the strength of each limb during movement. Outputs include activity counts and raw acceleration data.

Time frame
monthly, through study completion, an average of 6 months
3

Medications, Supplements, and Clinical Trial Participation Surveys

Participants complete questionnaires describing usage information about medications and supplements they have taken and are currently taking, as well as clinical trial participation.

Time frame
quarterly, through study completion, an average of 1 year
4

Social and Environmental Surveys

Participants complete questionnaires about their familial, educational, and geographical background, as well as lifestyle habits and past medical conditions and injuries. These are non-current factors that may have an affect on current health outcomes.

Time frame
One-time or quarterly at months 1, 4, 7, 10

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.